ELV vs INBX · P/E 18, rev $199.13B vs rev $1.3M
Elevance Health Inc (ELV) versus Inhibrx Biosciences, Inc. (INBX) — a side-by-side from cached financials, not a winner call.
Elevance Health Inc (ELV) is a healthcare plans company listed on US.
Inhibrx Biosciences, Inc. (INBX) is a biotechnology company listed on US.
Latest reported ELV revenue for 2025-12-31 was $199.13B. Net income was $5.66B. Revenue was up 12.5% from 2024-12-31 to 2025-12-31. ELV currently screens at market cap $90.24B and trailing P/E 17.6.
Latest reported INBX revenue for 2025-12-31 was $1.3M. Net income was -$140.1M. Revenue was up 550.0% from 2024-12-31 to 2025-12-31. INBX currently screens at market cap $1.28B.
ELV currently screens at market cap $90.24B and trailing P/E 17.6. INBX currently screens at market cap $1.28B.
Not investment advice. Open the ELV and INBX stock pages for the full models.
Not investment advice.